Klin Onkol 2015; 28(Suppl 4): 77-81. DOI: 10.14735/amko20154S77.
Summary Immunotherapy is becoming another possible alternative in the treatment of lung cancer. It is a completely different method of treating cancer which is not directed to the tumor itself, but to the immune system. Surface antigens present on tumor cells may be an effective and specific therapeutic targets and strategies based on antibodies inhibiting immune check points signifi cantly improves the anti-tumor immune response. Monoclonal antibody block ing CTLA-4 (cytotoxic T-lymphocyte antigen) and PD- 1 receptor (protein programmed cell death) and its ligand PD-L1 showed clinical efficacy and nivolumab (anti-PD-1) was approved in 2nd line treatment squamous non-small cell lung cancer.
